ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases... Show more
ImmunityBio occupies a differentiated niche in oncology immunotherapy through its Cancer BioShield platform, built around ANKTIVA (nogapendekin alfa inbakicept). Unlike checkpoint inhibitors that remove brakes on existing T cells, ANKTIVA is designed to activate and expand NK cells and memory T cells, an approach aimed at producing durable immune responses. This mechanistic distinction underpins the company's market positioning in bladder cancer, where ANKTIVA plus BCG (Bacillus Calmette-Guérin, a standard intravesical immunotherapy) is now approved for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) as well as papillary-only disease.
The medium-term strategy centers on moving ANKTIVA earlier in the treatment journey. Success in the QUILT-2.005 trial in BCG-naïve patients — a larger, first-line population — would meaningfully expand the addressable market and reinforce the company's competitive moat. Beyond bladder cancer, early approvals in non-small cell lung cancer (NSCLC) in Saudi Arabia and a pipeline spanning lymphoma, glioblastoma, and other indications suggest the platform's reach could extend well beyond a single tumor type.
The most significant upcoming event is the planned year-end 2026 sBLA submission for ANKTIVA in BCG-naïve NMIBC, following the QUILT-2.005 trial meeting its primary endpoint. A favorable FDA review would unlock a first-line opportunity that analysts view as the central driver of future upside.
Additional catalysts include regulatory submissions for ANKTIVA plus checkpoint inhibitors in NSCLC across ex-U.S. markets and discussions with the FDA on a potential U.S. accelerated approval pathway, as well as recombinant BCG regulatory filings. Continued execution of the European launch — where the first patients were treated in late 2026 — also matters for near-term revenue visibility.
Analyst sentiment has turned more constructive in response to these developments. Following the October 2026 label expansion, Jefferies raised its price target to $14 from $12, while Piper Sandler lifted its target to $16 from $12, both maintaining Buy ratings; H.C. Wainwright reiterated a $15 target. The consensus recommendation remains a "Strong Buy," with 12-month price targets generally clustering between roughly $12 and $16.
ImmunityBio's trajectory is shaped less by conventional macro variables and more by healthcare-specific dynamics. Reimbursement mechanics, clinical guideline adoption, and physician prescribing patterns in urology practices are the practical forces that will determine whether ANKTIVA converts early-adopter interest into routine use. A permanent J-code for streamlined U.S. billing and recent National Comprehensive Cancer Network guideline updates are supportive structural tailwinds.
On the macro side, interest rates and financing conditions remain relevant because the company is not yet cash-flow positive. Sustained losses, negative equity, and ongoing cash burn mean access to capital markets influences the pace at which ImmunityBio can fund trials and commercial expansion. Broader investor appetite for high-growth, pre-profit biotech equities — often sensitive to shifts in rate expectations and risk sentiment — can therefore amplify volatility in the share price independent of fundamental progress.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the coming week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments, with searchable prediction categories, historical context, and alert-oriented functionality. For investors monitoring a high-volatility name like IBRX, the engine can serve as a supplementary signal alongside fundamental and regulatory analysis. Consider exploring the tool to see how its momentum-based outlook compares with your own research.
Looking into 2026 and beyond, the central theme is whether ImmunityBio can convert a promising platform into sustained, profitable scale. The move into BCG-naïve NMIBC represents the clearest structural growth opportunity, as it targets a substantially larger population than the current BCG-unresponsive label. International commercialization across Europe, the Middle East, and other markets provides a second leg of growth, though reimbursement timelines vary by country.
Longer term, cost-structure evolution and margin sustainability will be closely watched. Gross margins on ANKTIVA are high, but the company's cost base remains disproportionate to revenue, and reaching operating profitability will require continued revenue ramp and disciplined spending. Competitive threats, evolving regulatory review timelines, and capital-allocation priorities around pipeline investment versus commercial buildout will shape sentiment. Consensus revenue estimates project continued rapid growth into 2026, but external price targets should be read as analyst expectations rather than forecasts. As ever, the durability of adoption and the timing of the FDA's review of the BCG-naïve filing are the variables most likely to define the stock's future outlook.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AIPO | 31.23 | N/A | N/A |
| Defiance AI & Power Infrastructure ETF | |||
| RCLR | 51.63 | N/A | N/A |
| Reckoner BBB-B Clo Reinvesting ETF | |||
| COWZ | 70.51 | -0.68 | -0.96% |
| Pacer US Cash Cows 100 ETF (COWZ) | |||
| NAPR | 59.44 | -0.67 | -1.12% |
| Innovator Growth-100 Power Buffer ETF - April (NAPR) | |||
| XBOC | 35.94 | -0.43 | -1.18% |
| Innovator U.S. Equity Accelerated 9 Buffer ETF - October (XBOC) | |||
A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To IBRX | 1D Price Change % | ||
|---|---|---|---|---|
| IBRX | 100% | -0.66% | ||
| AXON - IBRX | 48% Loosely correlated | -2.85% | ||
| ARRY - IBRX | 41% Loosely correlated | -3.51% | ||
| QTTB - IBRX | 39% Loosely correlated | -4.82% | ||
| NTLA - IBRX | 38% Loosely correlated | +1.65% | ||
| FTH - IBRX | 37% Loosely correlated | -7.48% | ||
More | ||||
a producer of cancer treatment products
Industry Biotechnology
IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 33 cases where IBRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in 212 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRX as a result. In 84 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for IBRX turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 46 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
IBRX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IBRX crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for IBRX entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.744) is normal, around the industry mean (3.586). P/E Ratio (-9.089) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (47.847) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.